Provided by Tiger Fintech (Singapore) Pte. Ltd.

Q32 Bio Inc.

2.00
+0.16008.70%
Post-market: 2.000.00000.00%16:05 EDT
Volume:121.08K
Turnover:237.01K
Market Cap:24.40M
PE:-0.30
High:2.01
Open:1.85
Low:1.85
Close:1.84
Loading ...

Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures

TIPRANKS
·
12 Mar

Q32 Bio Q4 2024 GAAP EPS $(1.16) Beats $(1.51) Estimate, Cash And Cash Equivalents Of $78M As Of December 31, 2024 Expected To Provide Financial Runway Into 2H 2026

Benzinga
·
11 Mar

Press Release: Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Dow Jones
·
11 Mar

Q32 Bio Presents Results From Signal-Aa Part a Clinical Trial Evaluating Bempikibart in Patients With Alopecia Areata at the 2025 American Academy of Dermatology Meeting

THOMSON REUTERS
·
09 Mar

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

PR Newswire
·
09 Mar

Q32 Bio Inc expected to post a loss of $1.51 a share - Earnings Preview

Reuters
·
07 Mar

Q32 Bio Announces Late-Breaking Presentation of Results From Signal-Aa Part a Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

THOMSON REUTERS
·
28 Feb

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

PR Newswire
·
28 Feb

Q32 Bio to Participate in Upcoming March Investor Conferences

PR Newswire
·
26 Feb

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Q32 Bio (QTTB) and Vaxcyte (PCVX)

TIPRANKS
·
13 Feb

Q32 Bio Inc : Bmo Cuts to Market Perform From Outperform; Cuts Target Price to $3 From $22

THOMSON REUTERS
·
12 Feb

Q32 Bio Unveils Restructuring to Focus on Alopecia Areata Treatment; Shares Fall

MT Newswires Live
·
12 Feb

Q32 Bio Cut to Market Perform From Outperform by BMO Capital

Dow Jones
·
11 Feb

Piper Sandler Downgrades Q32 Bio to Neutral From Overweight, Adjusts Price Target to $4 From $20

MT Newswires Live
·
11 Feb

Q32 Bio Cut to Neutral From Overweight by Piper Sandler

Dow Jones
·
11 Feb

Q32 Bio downgraded to Neutral from Overweight at Piper Sandler

TIPRANKS
·
11 Feb